Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

stigational New Drug (IND) application with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology.

-- Additional receipts related to the sale of products to be paid by Mayne Pharma are anticipated during 2008 in a range from $1.6 million to $2.6 million. These payments will be classified as gain on sale of products.

-- Included in total operating expenses for 2008 is a reduced amount from previous guidance for non-cash stock-based compensation expense estimated at $3.5 million annually.

-- Based on the revised 2008 financial guidance loss from operations is estimated in a range from $16.6 million to $18.6 million.

-- Revised weighted average shares outstanding for 2008 are estimated at 58.1 million common shares.

Recent Corporate Events:

-- April 2008: The Company had multiple abstracts accepted for oral and

poster presentation at the American Association of Cancer Research

(AACR) Annual Meeting, that took place April 12-16 in San Diego,

California. Highlights of the presentations are included below:

-- SGI-1776, our lead pre-clinical PIM kinase inhibitor, was found to

cause tumor regression in acute myelogenous leukemia (AML) xenograft

models (Abstract No. 4974). In an oral presentation entitled, "A

potent small molecule PIM kinase inhibitor with activity in cell

lines from hematological and solid malignancies," Dr. Steven Warner,

SuperGen's Manager, Discovery Biology, detailed how scientists used

the Company's CLIMB(TM) technology to build a model that allowed for

the creation of small molecule PIM kinase inhibitors. SGI-1776 was

identified as a potent and selective inhibitor of the PIM kinases,

inducing apoptosis and cell cycle arrest, thereby causing a

reduction in phospho-BAD levels and enhancement of mTOR inhibit
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2
... 6 Today, Pepscan reports,that it has achieved ... its,CLIPS-based synthetic peptide immunogen technology. By constructing synthetic,3D ... has induced functional,antibodies against the formerly intractable GPCR ... be involved in tumor angiogenesis. , ...
... today a strategic partnership with Scottsdale Clinical Research Institute ... cutting edge knowledge discovery and collaboration tools at ... more access to the latest therapies to treat cancer ... and communicate with each other about difficult cases. ...
... Communications Solution Demonstrated at HIMSS 2009BERKELEY HEIGHTS, N.J., ... (Nasdaq: ADAT ), a worldwide provider ... services, today announced that it has integrated Authentidate,s ... to improve hospital patient discharges. "Hospitals are looking ...
Cached Biology Technology:Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7 2MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 3Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 4
(Date:9/2/2014)... MD - The American Society of Human Genetics ... (NHGRI), part of the National Institutes of Health, ... at Northwestern University in Chicago, the newest ASHG/NHGRI ... begins today. , The Genetics and Public Policy ... develop and implement genetics-related health and research policy ...
(Date:9/2/2014)... PARK, Md. -- A team of University of ... they and other scientists say make possible new ... from clean energy and quantum computing advances to ... 2, issue of Nature Communications the ... synthesis strategy for hybrid nanostructures that uses a ...
(Date:9/2/2014)... [Brown University] It,s hard to comprehend how bad ... has become without knowing what it was before people ... rate was 10 times lower than scientists had thought, ... worse. , Extinctions are about 1,000 times more frequent ... came along. The explanation from lead author Jurriaan de ...
Breaking Biology News(10 mins):ASHG and NHGRI award genetics and public policy fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... The Scripps Research Institute (TSRI) and the Takeda ... research collaboration to search for new drug targets for ... an initial collaboration launched in 2010 between scientists on ... led to several breakthroughs in identifying potential new compounds ...
... release is available in French . ... Sciences and his colleagues have unearthed a major scientific discovery ... Shale fossil beds, located in Yoho National Park. The fossils ... 505 million years old., Their study, to be published online ...
... March 13, 2013 Even after researchers studying White Nose ... is at the heart of the devastating disease, detecting ... This month, the journal Mycologia will publish research ... identifying additional species of Geomyces and describing development ...
Cached Biology News:Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration 2Strange phallus-shaped creature provides crucial missing link 2More accurate, sensitive DNA test allows early identification of fungus causing WNS 2
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Biology Products: